×
About 42,583 results

ALLMedicine™ Acute Myeloid Leukemia Center

Research & Reviews  12,610 results

Cytomegalovirus-Specific T Cells from Third-Party Donors Successfully Treated Refractor...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9681565
Journal of Immunology Research; Li N, Sun G et. al.

Nov 26th, 2022 - Umbilical cord blood (UCB) transplants (UCBTs) are becoming increasingly common in the treatment of a variety of hematologic and nonhematologic conditions. The T cells from UCB are naïve T cells, which have not yet been exposed to antigens and the...

Sex differences in adults with acute myeloid leukemia and the impact of sex on overall ...
https://doi.org/10.1002/cam4.5461
Cancer Medicine; Stabellini N, Tomlinson B et. al.

Nov 25th, 2022 - There is a male predominance of acute myeloid leukemia (AML) incidence, but survival data are conflicting. The objective of this study is to carry out a comprehensive analysis of sex differences in AML, and to investigate the impact of sex dispari...

Moving towards individualized target-based therapies in acute myeloid leukemia.
https://doi.org/10.1016/j.annonc.2022.11.004
Annals of Oncology : Official Journal of the European Soc... Bazinet A, Kantarjian HM

Nov 25th, 2022 - Acute myeloid leukemia (AML) is a heterogeneous disease at the genetic level. The field of AML therapy is increasingly shifting away from uniform approaches based solely on intensive chemotherapy (such as "7 + 3") towards personalized therapy. The...

Economic Impact of Transformation to Acute Myeloid Leukemia Among Actively Managed Pati...
https://doi.org/10.1007/s12325-022-02370-4
Advances in Therapy; Kota V, Ogbonnaya A et. al.

Nov 25th, 2022 - Transformation of higher-risk myelodysplastic syndromes (MDS) to acute myeloid leukemia (AML) may be associated with increased healthcare resource utilization (HCRU) and costs. To describe this economic impact, HCRU and costs were compared between...

Image-seq: spatially resolved single-cell sequencing guided by in situ and in vivo imag...
https://doi.org/10.1038/s41592-022-01673-2
Nature Methods; Haase C, Gustafsson K et. al.

Nov 25th, 2022 - Tissue function depends on cellular organization. While the properties of individual cells are increasingly being deciphered using powerful single-cell sequencing technologies, understanding their spatial organization and temporal evolution remain...

see more →

Guidelines  12 results

NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021.
https://doi.org/10.6004/jnccn.2021.0002
Journal of the National Comprehensive Cancer Network : JN... Pollyea DA, Bixby D et. al.

Jan 7th, 2021 - The NCCN Guidelines for Acute Myeloid Leukemia (AML) provide recommendations for the diagnosis and treatment of adults with AML based on clinical trials that have led to significant improvements in treatment, or have yielded new information regard...

Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myel...
https://doi.org/10.1016/j.bbmt.2020.09.020
Biology of Blood and Marrow Transplantation : Journal of ... Dholaria B, Savani BN et. al.

Sep 24th, 2020 - The role of hematopoietic cell transplantation (HCT) in the management of newly diagnosed adult acute myeloid leukemia (AML) is reviewed and critically evaluated in this evidence-based review. An AML expert panel, consisting of both transplant and...

Clinical Practice Guideline for Systemic Antifungal Prophylaxis in Pediatric Patients W...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7499615
Journal of Clinical Oncology : Official Journal of the Am... Lehrnbecher T, Fisher BT et. al.

May 28th, 2020 - To develop a clinical practice guideline for systemic antifungal prophylaxis in pediatric patients with cancer and hematopoietic stem-cell transplantation (HSCT) recipients. Recommendations were developed by an international multidisciplinary pane...

NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018.
https://doi.org/10.6004/jnccn.2017.0157
Journal of the National Comprehensive Cancer Network : JN... Mesa RA, Jamieson C et. al.

Oct 7th, 2017 - Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders of the hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). PV and ET are characterized by significant thromboh...

Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2017.0116
Journal of the National Comprehensive Cancer Network : JN... O'Donnell MR, Tallman MS et. al.

Jul 9th, 2017 - Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. This portion of the NCCN Guidelines for AML focuses on management and p...

see more →

Drugs  32 results see all →

Clinicaltrials.gov  1,717 results

Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
https://clinicaltrials.gov/ct2/show/NCT04774393

Oct 14th, 2022 - PRIMARY OBJECTIVE: I. To determine the safety and tolerability and recommended phase 2 dose (RP2D) of oral decitabine/cedazuridine (ASTX727) and venetoclax in combination with either ivosidenib (Arm A) or enasidenib (Arm B) for patients with acute...

Longitudinal Studies of Patient With FPDMM
https://clinicaltrials.gov/ct2/show/NCT03854318

Oct 14th, 2022 - Germline mutations in RUNX1 are responsible for familial platelet disorder with associated myeloid malignancies (FPDMM, or simply FPD), an autosomal dominant disease characterized by defective megakaryocytic development, low platelet counts, prolo...

AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia
https://clinicaltrials.gov/ct2/show/NCT02675452

Oct 14th, 2022 - This is a Phase 1, first-in-human, multicenter; non-randomized, open-label and dose-exploration study of AMG 176 administered IV in participants with relapsed or refractory multiple myeloma and participants with relapsed or refractory acute myeloi...

A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
https://clinicaltrials.gov/ct2/show/NCT02421939

Oct 14th, 2022 - Participants considered an adult according to local regulations at the time of signing informed consent may participate in this study. Participants will be randomized in a 2:1 ratio to receive ASP2215 or salvage chemotherapy. Participants will ent...

BMS-986253 in Myelodysplastic Syndromes
https://clinicaltrials.gov/ct2/show/NCT05148234

Oct 14th, 2022 - Background: The myelodysplastic syndromes (MDS) are a group of clonal bone marrow neoplasms characterized by ineffective hematopoiesis, cytopenia, and high risk for transformation to acute myeloid leukemia (AML). MDS is primarily a disease of the ...

see more →

News  2,648 results

Novel Treatments Begin to Rival Transplant in AML and DLBCL
https://www.onclive.com/view/novel-treatments-begin-to-rival-transplant-in-aml-and-dlbcl

Nov 21st, 2022 - The fields of diffuse large B-cell lymphoma (DLBCL) and acute myeloid leukemia (AML) are quickly expanding to accommodate novel therapies such as polatuzumab vedotin-piiq (Polivy) plus R-CHOP (rituximab [Rituxan], cyclophosphamide, doxorubicin, vi...

First Patient Dosed With Menin Inhibitor BMF-219 in COVALENT-101 Trial in CLL
https://www.onclive.com/view/first-patient-dosed-with-menin-inhibitor-bmf-219-in-covalent-101-trial-in-cll

Nov 21st, 2022 - The first patient in the chronic lymphocytic leukemia (CLL) cohort has been dosed in the phase 1 COVALENT-101 trial (NCT05153330), which is evaluating the first-in-class covalent menin inhibitor BMF-219, in patients with relapsed/refractory acute ...

SOLO-1 Data Support Use of Olaparib Maintenance to Achieve Long-Term Remission in BRCA+ Advanced Ovarian Cancer
https://www.onclive.com/view/solo-1-data-support-use-of-olaparib-maintenance-to-achieve-long-term-remission-in-brca-advanced-ovarian-cancer

Nov 17th, 2022 - Seven-year follow-up data from the phase 3 SOLO-1/GOG-3004 trial (NCT01844986) provide further confirmation of the long-term survival benefit achieved with maintenance treatment with olaparib (Lynparza) vs placebo in patients with newly diagnosed,...

Niraparib Maintenance Produces Long-Term Benefit in Advanced Ovarian Cancer, Irrespective of HRD Status
https://www.onclive.com/view/niraparib-maintenance-produces-long-term-benefit-in-advanced-ovarian-cancer-irrespective-of-hrd-status

Nov 17th, 2022 - Frontline niraparib (Zejula) maintenance sustained a progression-free survival (PFS) benefit in patients with advanced ovarian cancer, according to updated data from the phase 3 PRIMA trial (NCT02655016) presented at the 2022 ESMO Congress. Notab...

Dr. Perl on Genetic Testing and Targeted Therapies in AML
https://www.onclive.com/view/dr-perl-on-genetic-testing-and-targeted-therapies-in-aml

Nov 10th, 2022 - Alexander E. Perl, MD, MS, associate professor, medicine, the Hospital of the University of Pennsylvania, discusses why genetic testing is important for determining targeted therapies for patients with acute myeloid leukemia (AML). Newer targeted...

see more →

Patient Education  14 results see all →